BIOBUCKS MANIFESTO (NOV 30 2015)

Transactional Case Studies
  1. Sosei/Heptares-Pfizer for up to 10 GPCR targets | Upfront undisclosed | $189M milestones/target | Tiered royalties on net sales/target | Pfizer $33M equity investment into Sosei/Heptares
  2. Takeda-Teva Generics JV for Japan Territory
  3. Roche exits Polyphor antibiotics collaboration
  4. Upsher-Smith-Roche oral VAP-1 antagonist against lymphocyte trafficking Phase II osteoarthritis collaboration
  5. XOMA-Novo Nordisk XMetA allosteric monoclonal antibodies as partial agonist against the insulin receptor for diabetes | $5M upfront | $290M milestones | tiered royalties on sales
  6. 3SBio buys 47% equity of Guojian China biosimilars for $213M
  7. Almirall buys Poli Group dermatology for $386M+$37M development milestones
  8. Viromed (Korea)-Bluebird CAR-T for solid tumors | $1M upfront | $48M milestones total | tiered royalty on sales
  9. Egalet exits Shionogi P1 abuse-deterrent extended release hydrocodone collaboration
  10. Zymeworks-GSK for up to 4 novel Fc engineered mAbs | $110M+ milestones /target | tiered royalty on sales
  11. Kite-GE engineered T-cells manufacturing collaborative research
  12. JNJ-Novira P1b oral HBV NBR3-778 direct-acting antiviral acquisition
  13. Amgen-Merck AMG820 Keytruda DLBCL clinical collaboration
  14. KaloBios buys Savant's benznidazole against Chaga's Disease for $2M + regulatory milestones + royalties on sales